UBC Medical Indonesia Tbk. vs Merck Tbk. — how do they compare? UBC Medical Indonesia Tbk. trades at Rp148 (market cap 576.7B, 3.48M 24h volume), while Merck Tbk. trades at Rp3,840 (market cap 1.7T, 37.6K 24h volume). The key difference: Merck Tbk. is far larger — about 2.9× UBC Medical Indonesia Tbk.'s market cap, and UBC Medical Indonesia Tbk. is more actively traded (3.48M versus 37.6K). Which is the better fit depends on your goals.
| LABS | MERK | |
|---|---|---|
Market Cap | 576.7B | 1.7T |
Volume | 3.48M | 37.6K |
Lot | 34.82K | 376 |
Turnover | 522.79M | 144.47M |
Average Price | 150.13 | 3,842.23 |
Value | 522.79M | 144.47M |
Indicative Equilibrium Price | 148 | 3,840 |
Indicative Equilibrium Volume | 350 | 7 |
Trailing returns across standard periods
Latest headlines on both assets
PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.
Read more on LABS →PT Merck Tbk (the Company) is domiciled in Indonesia and located at Jl. TB Simatupang No. 8, Pasar Rebo, East Jakarta, was established in framework of Law No. 1 of 1967 and Law No. 11 of 1970 on foreign capital investment by deed of notary public Eliza Pondaag, SH dated 14 October 1970 No. 29. PT Merck Indonesia is a member of the Merck International Group. The company produces pharmaceutical products with production facility in East Jakarta. It commenced its operation in 1974 in manufacturing medical products, such as Songobian and Neurobion.
Read more on MERK →